Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bioventus (BVS) Revenue (2020 - 2025)

Bioventus (BVS) has disclosed Revenue for 6 consecutive years, with $157.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Revenue rose 2.77% year-over-year to $157.9 million, compared with a TTM value of $568.1 million through Dec 2025, down 0.91%, and an annual FY2025 reading of $568.1 million, down 0.91% over the prior year.
  • Revenue was $157.9 million for Q4 2025 at Bioventus, up from $138.7 million in the prior quarter.
  • Across five years, Revenue topped out at $157.9 million in Q4 2025 and bottomed at $81.8 million in Q2 2021.
  • Average Revenue over 5 years is $129.8 million, with a median of $129.9 million recorded in 2021.
  • The sharpest move saw Revenue skyrocketed 89.28% in 2021, then decreased 6.12% in 2023.
  • Year by year, Revenue stood at $130.4 million in 2021, then dropped by 3.51% to $125.8 million in 2022, then grew by 7.62% to $135.4 million in 2023, then rose by 13.45% to $153.6 million in 2024, then rose by 2.77% to $157.9 million in 2025.
  • Business Quant data shows Revenue for BVS at $157.9 million in Q4 2025, $138.7 million in Q3 2025, and $147.7 million in Q2 2025.